These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12901037)

  • 1. Applying patient selection criteria for drotrecogin alfa therapy in practice.
    Wong-Beringer A; Liao C; Nguyen M; Pallares J
    Am J Health Syst Pharm; 2003 Jul; 60(13):1345-52. PubMed ID: 12901037
    [No Abstract]   [Full Text] [Related]  

  • 2. Criteria for use of drotrecogin alfa.
    Jacobi J
    Am J Health Syst Pharm; 2004 Jan; 61(2):203-4; author reply 204-5. PubMed ID: 14750407
    [No Abstract]   [Full Text] [Related]  

  • 3. Criteria for use of drotrecogin alfa.
    Mann HJ
    Am J Health Syst Pharm; 2004 Jan; 61(2):202; author reply 204-5. PubMed ID: 14750406
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand.
    Finfer S; Felton T; Blundell A; Lipman J;
    Anaesth Intensive Care; 2006 Apr; 34(2):184-90. PubMed ID: 16617638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?
    Ahishakiye D; Lorent S; De Backer D; Gottignies P; Vincent JL
    J Crit Care; 2009 Dec; 24(4):590-4. PubMed ID: 19577419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies.
    Cohen H; Welage LS
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):223S-235S. PubMed ID: 12492229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
    Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
    Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 15. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 16. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
    Scipione MR; Nogid B; Davanos E; DiGregorio RV
    Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of drotrecogin alfa depends on severity of illness.
    Deans KJ; Minneci PC; Eichacker PQ; Natanson C
    Crit Care Med; 2004 Nov; 32(11):2347. PubMed ID: 15640655
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 19. Drotrecogin alfa (activated): is there room for improvement?
    Cunningham K; Jankovic Z
    Eur J Anaesthesiol; 2008 Nov; 25(11):952. PubMed ID: 18533075
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.